Major depressive disorder is a debilitating neurodegenerative disorder which afflicts approximately 14-20% of the general population; of those individuals, approximately 30% are treatment resistant to antidepressant medications. Recently, the FDA has approved a novel antidepressant, Zuranolone for use in individuals who suffer from postpartum depression and, this drug has shown very promising results. Using 488uM thick hippocampal brain slices, local field potential (LFP) recordings were conducted and analyzed for changes in sharp wave ripple (SWR) complexes. In order to assess in-vivo changes with Zuranolone treatment, C57BL/6 mice were injected with a 10mg/kg dose of the drug for a period of five days. Mice were subsequently euthanized and brains were assessed for changes markers of neural plasticity through Western blot analysis and immunohistochemical analysis. Through the use of LFP recordings and analyses, changes in SWR complexes within the LFP were confirmed in hippocampal brain slices following treatment with Zuranolone compared to their baseline activity. From Western blot analyses, changes in perineuronal net components from whole hippocampal lysates such as brevican, aggrecan, and HAPLN2 have been detected. Behaviorally, mice show no minimal differences in elevated plus maze, elevated zero maze, and open field testing, but more cohorts to increase the overall number of mice in experiments will be part of future experiments. Findings have potential to support the importance structural changes and changes in neuronal population activity through extracellular matrix remodeling which could potentially alleviate a depressive-like phenotype in the mouse model.